MoonLake Immunotherapeutics(US:MLTX) Globenewswireยท2025-10-02 14:46Core Points - Bragar Eagel & Squire, P.C. is investigating potential claims against MoonLake Immunotherapeutics for possible violations of federal securities laws and unlawful business practices [1][2][4] - MoonLake's stock experienced a significant decline of 89.9% on September 29, 2025, following the announcement of disappointing results from its VELA-2 trial, which failed to achieve statistical significance [1][6] Investigation Details - The law firm is reaching out to investors who purchased or acquired MoonLake shares and suffered losses, encouraging them to discuss their legal rights and options [1][3] - The investigation is focused on whether the company misled investors regarding its trial results and overall business practices [1][2] Company Background - Bragar Eagel & Squire, P.C. is a nationally recognized law firm with a focus on representing individual and institutional investors in complex litigation [4] - The firm operates in multiple states, including New York, South Carolina, and California, and has a track record in commercial and securities litigation [4]